Abstract

Naltrexone Hydrochloride 0.5 mg/mL and 5.0 mg/mL in SuspendIt Suspension

Author(s): Allen Loyd V Jr

Issue: May/Jun 2021 - Volume 25, Number 3

Page(s): 233

Download in electronic PDF format for $75

Abstract

A formulation for preparing Naltrexone Hydrochloride 0.5 mg/mL and 5.0 mg/mL in SuspendIt Suspension. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
May/Jun 2021 Pg. 233	Naltrexone Hydrochloride 0.5 mg/mL and 5.0 mg/mL in SuspendIt Suspension Author(s): Allen Loyd V Jr
May/Jun 2004 Pg. 181-185	Compounding in the Pharmacy Curriculum: Beyond the Basics Author(s): Hinkle Amanda R, Newton Gail D
Nov/Dec 2004 Pg. 462-465	Basics of Compounding for Cough Author(s): Allen Loyd V Jr
May/Jun 2013 Pg. 235	Naltrexone Hydrochloride 50-mg Capsules Author(s): Allen Loyd V Jr
Mar/Apr 2019 Pg. 157-162	Physicochemical Stability of Compounded Naltrexone Hydrochloride Solutions in PCCA Base SuspendIt Author(s): Pramar Yashoda V, Mandal Tarun K, Bostanian Levon A, Nguyen Anh TQ, Morris Tommy C, Graves Richard A
Nov/Dec 2018 Pg. 516-526	Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4 Author(s): Polonini Hudson, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
Jul/Aug 2009 Pg. 296-299	Compounding Naltrexone for the Treatment of Autism Author(s): Wynn Tom, Brunetti Sarah
Jan/Feb 2005 Pg. 67	Naltrexone Hydrochloride 1.4-mg/mL Injection, Preservative Free Author(s): Allen Loyd V Jr
Jan/Feb 2000 Pg. 17-20	Opioids: A Review of the Pharmacology Author(s): Ford Peter R
Jan/Feb 2021 Pg. 43	Amlodipine Besylate 0.5-mg/mL to 10-mg/mL in SuspendIt Oral Suspension Author(s): Allen Loyd V Jr
Nov/Dec 2006 Pg. 459	Naltrexone 1-mg/mL Oral Liquid Author(s): Allen Loyd V Jr
Sep/Oct 2003 Pg. 389-393	Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride Author(s): Alexander Kenneth S, Thyangarajapuram N
May/Jun 2008 Pg. 274-275	Chemical Stability of Naltrexone Hydrochloride Injection Author(s): Gupta Vishnu D
Jul/Aug 2018 Pg. 270-278	Compounded Low-dose Naltrexone for the Treatment of Guttate Psoriasis: A Case Report Author(s): Muller George, Grieshaber Robert, Talley J Floyd, Riepl Mike, Fellows Don
Nov/Dec 2011 Pg. 504	Morphine 6-mg/mL, Haloperidol 0.5-mg/mL, and Hyoscine 6-mg/mL Infusion Author(s): Allen Loyd V Jr
May/Jun 2012 Pg. 244	Naloxone Hydrochloride 1-mg/mL Injection Author(s): Allen Loyd V Jr
May/Jun 2016 Pg. 197-201	Low-Dose Naltrexone: A New Therapy Option for Complex Regional Pain Syndrome Type I Patients Author(s): Sturn Kayla M, Collin Michael
May/Jun 2018 Pg. 252-256	The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia Author(s): Cote Brianna, Ross Bethany, Fortner Jeff, Rao Deepa
Jan/Feb 2004 Pg. 46-48	Basics of Compounding for Disorders of the External Ear Author(s): Allen Loyd V Jr
Nov/Dec 2002 Pg. 455	Methadone HCl 1-mg/mL, 2-mg/mL, and 5-mg/mL Injection Author(s): Allen Loyd V Jr